FRONTIER BIOTECHNOLOGIES

Frontier is an innovation-driven biopharmaceutical company. Through more than a decade of committed effort, Frontier Biotech has built an extraordinary team with international vision and deep expertise in new drug development and established a fully integrated state-of-the-art long-acting peptide new drug innovation platform with global intellectual properties. In addition to the launch of Aikening®, a Category 1 product and the first long-acting HIV fusion inhibitor in the world, Frontier Biotech is advancing an array of clinical assets through our R&D pipeline. This includes multiple programs reaching Phase 1 and 2 clinical trials in China and the United States.